All Viral Vector Services

Master Cell Bank (MCB) and Working Cell Bank (WCB) are the foundation of biologics
manufacturing. The quality of these banks determines future manufacturing performance,
impacting product safety, stability and regulatory compliance. At Minaris, we generate, expand
and test GMP cell banks for various cell lines, supported by full viral safety testing, release and
long-term storage.

AAV supply has long been constrained by high costs, low yields, and scalability challenges. Minaris’ proprietary TESSA® technology changes that equation. Delivering 10–50x higher AAV vector productivity than conventional triple plasmid transfection, TESSA® enables cost saving (>90%) per dose and large-scale manufacturing without compromising quality. The platform has been validated across multiple serotypes—including AAV1, AAV2, AAV4–AAV9, AAVrh8, AAVrh10 and AAVrh74—with ranging from up to 50-80% full capsids in crude harvest.

Our TESSA® technology is fully integrated with in-house testing capabilities, including biosafety assessments, viral clearance, and product release testing. By combining higher titers with superior quality, TESSA® offers a proven path to meeting the market’s growing demand for reliable clinical and commercial AAV supply.

XOFLX™ packaging and producer cell lines stably express genes needed for LVV production, eliminating the need and expense of multiple plasmids. The system utilizes an integrated Tet-inducible VSV-G and Gag-Pol expression strategy and is engineered for low homology between expression cassettes for an improved safety profile. The XOFLX™ cell line was selected for high growth and viability, low aggregation and high productivity. Its robust scalability and low complexity process results in decreased batch-to-batch variation.

At Minaris, we support innovators by developing and optimizing robust producer cell lines tailored to program needs. Our integrated services span vector design and construction, clone selection, stability testing and tech transfer. With the right producer cell line strategy, advanced therapy developers can unlock scalable, cost-effective production while maintaining the quality and safety demanded by regulators and patients. Minaris brings the scientific rigor and manufacturing experience to make that possible.

At Minaris, our experts have established robust platform processes for both AAV and LVV, ensuring yield and purity that meet stringent program requirements. We leverage AMBR15/250 alongside 2-200L bioreactors to move seamlessly from design-of-experiment (DoE) studies through pilot-scale production. With integrated features, Minaris provides a flexible pathway for viral vector process development, optimizing production, scaling up processes, reducing risks, and accelerating timelines.

Minaris delivers clinical and commercial GMP manufacturing of viral vectors from US-based facilities designed for scale and flexibility. Our state-of-the-art suites support adherent processes up to 60-Hyperstacks and suspension culture from 50L to 2,000L. Built with scalability in mind, we leverage single-use technologies, close system and multi-product production suites to ensure regulatory compliance, product quality, and efficient tech transfer. From early clinical supply to full commercial manufacturing, Minaris provides the infrastructure and expertise to accelerate advanced therapy programs.